PRD Therapeutics, inc. is a Startup from Kitasato University that develops new drugs for lipid metabolism diseases such as NASH/NAFLD and Homozygous-Familial hypercholesterolemia using the orally administrable First-in-Class inhibitor PRD001.

PRD001 is an orally available, natural product based, lead-optimized small molecule compound. PRD001 has a novel MOA of SOAT2-PCSK9 dual inhibition, which strongly lowers blood lipids. PRD001 is the IND-enabling study stage compound with plans to begin Phase I clinical trials in 2024. We are looking for the partner-, out-licensing- pharmaceutical companies.